【独家药企专访】世和一号®FDA获批：如何破局新药开发与精准医疗国际壁垒
世和一号®成功跻身国际舞台，不仅实现了中国智造在精准医疗领域的全球“领跑”，也为解决全球检测标准不统一导致的新药开发困境，提供了极具价值的选择。
Time：
2025-09-09 10:39
Author：
Recommended content
WCLC 2026 | Hansun "Blows the Roof Off", the New King of B7-H3 ADC is About to be Crowned
It's time for Chinese innovative drugs to redefine the standards.
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务